Peter D. Byeff

Hematology | Oncology
55 Meriden Ave Ste 1A
Southington, CT 06489

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Journal: Leukemia & lymphoma
Published: April 10, 2020
Showing 1-1 of 1

Last Updated: 09/26/2026